OBiS Announces Results from a Global Breast Cancer Survey
Global breast cancer survey demonstrates physicians generally prefer standard of care chemotherapy as compared to newly approved targeted therapies
NEW YORK, March 11, 2014 /PRNewswire/ — OBiS releases preliminary results from its 2014 global physician breast cancer survey. The survey included treatment data and insights from over 50 countries and 500 treating physicians.
Data demonstrated that despite a number of newly approved targeted therapies, most physicians treated their patients with more traditional standard of care chemotherapy options. Physicians answered that they only anticipate an increase in usage of the targeted agents Ado-Trastuzumab Emtansine and Pertuzumab. From our physician sample the majority of patients included in the analysis were adjuvant.
The survey is now closed and complete results and geographic analyses are available upon request.
OBiS is a leading consulting firm specializing in pharmaceutical, biotech and life-science consulting, OBiS has partnered with several pharmaceutical firms assisting in protocol feasibility and analytics, clinical site profiling, recruitment projections and forecasting, primary and secondary market research, ROI analyses, and validated physician databases. OBiS provides customizable strategic and analytical solutions. Our team consists of professionals with extensive pharmaceutical experience and advanced degrees in science and business.
Please visit our website (www.obis.com) and connect with us on LinkedIn for additional services and information.
Contact: Rick Beasley, 212-254-2509